Gilead's HIV Quad meets primary endpoint, but not investors' expectations
This article was originally published in Scrip
With the hype that has been building around Gilead's once-daily, fixed-dose, four-in-one HIV pill, dubbed Quad – emtricitabine, tenofovir disoproxil fumarate, evitegravir and cobicsta – one would think investors’ reaction to positive top-line Phase III results on 15 August would be more favourable. But alas, it was mostly disappointment, with the firm's stock losing as much as $1.25, or 3.3%, before closing $37.27, a loss of 16 cents.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.